Brentuximab vedotina per al tractament de la malaltia de Hodgkin: informe d'avaulació de resultats
Abstract
Lymphoma or Hodgkin's disease is a neoplasm that affects the lymphatic tissue. Symptomatology includes the growth of lymph nodes, spleen and other immune tissues, as well as fever, weight loss, fatigue, night sweats and pruritus. The initial treatment includes chemotherapy and / or radiotherapy; the remission is achieved up to 80% of cases, but relapse rates range from 10% to 40%. The treatment of recurrences and refractory forms also includes chemotherapy, followed by autostroplacation of the bear's wharf when it is viable.
Keywords
Hodgkin's disease; Brentuximab vedotina; TreatmentBibliographic citation
Programa d'Harmonització Farmacoterapèutica. Brentuximab vedotina per al tractament de la malaltia de Hodgkin: informe d'avaulació de resultats. Barcelona: Servei Català de la Salut; 2018.
Audience
Professionals
This item appears in following collections
The following license files are associated with this item:




